Pavan Cheruvu, CEO of biotech firm Incyte and a former director at the World Health Organization. The drug was generally well tolerated, Axovant said, and signals were observed in secondary measures, including trends in certain sleep parameters and brain wave monitoring during sleep. In 2019, the company is anticipating phase II results from its AXO-Lenti-PD, a treatment for Parkinson’s disease, and plans to begin clinical trials for AXO-AAV-OPMD, which restores normal muscle function in patients with oculopharyngeal muscular dystrophy.
Pavan Cheruvu, CEO of biotech firm Incyte and a former director at the World Health Organization. In 2019, the company is anticipating phase II results from its AXO-Lenti-PD, a treatment for Parkinson’s disease, and plans to begin clinical trials for AXO-AAV-OPMD, which restores normal muscle function in patients with oculopharyngeal muscular dystrophy.